Washington, D.C. (November 30, 2018) – Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the United States-Mexico-Canada Agreement (USMCA):“The signing of today’s trade agreement has effectively prioritized biotechnology innovation across North America by updating intellectual property protections and agricultural market access to 21st century standards. The USMCA is a major step towards bringing Mexico and Canada closer to the standards that has made the United States the world leader in biotechnology innovation.“Strong and dependable intellectual property standards are critical to fueling innovation, attracting investment, and ensuring that patients, farmers, and consumers around the globe have access to the next generation of biotechnology breakthroughs. Thanks to the Trump Administration’s leadership, the United States and our neighboring countries will continue to drive global innovation, ingenuity and ground-breaking science.”###

Brent Erickson, Executive Vice President of the Biotechnology Innovation Organization’s (BIO) Industrial and Environmental Section, released the following statement today on final Renewable Fuel Standard (RFS) volumes for 2019 and the Biomass-Based Diesel Volumes for 2020 published by the Environmental Protection Agency (EPA):

“I applaud Chairman Brady and his colleagues on the House Ways & Means Committee for recognizing the unintended consequences faced by far too many small business innovators today due to NOL limitations."

The Biotechnology Innovation Organization (BIO) today announced preliminary programming for the upcoming BIO CEO & Investor Conference to be held February 11-12, 2019 in New York City. Program lineup covers policy, investment, innovation and patient access. New this year, BIO is offering Executive Leadership courses to help companies develop tools for striking deals and improving corporate reputation. Participants will choose between one of two interactive courses which are based on real-life biopharma experiences and will run on Sunday, February 10.

The Biotechnology Innovation Organization (BIO) issued the following statement regarding unsubstantiated reports this week of experiments involving heritable human genome editing in China.